Fundraising Fox
/Companies
Sign in

89bio (NASDAQ: ETNB)

acquired by Roche

San Francisco, US · 3 known investors

Find your way into 89bio (NASDAQ: ETNB)

Sign up to see every warm intro you have to 89bio (NASDAQ: ETNB)

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the 89bio (NASDAQ: ETNB) team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Acquired by Roche September 2025 · terms undisclosed — Up to $20.50 per share in cash ($14.50 at closing plus $6.00 CVR) · source ↗

A clinical-stage biopharmaceutical company developing investigational therapies for patients with liver and cardiometabolic diseases, with a lead candidate (pegozafermin) being evaluated for metabolic dysfunction-associated steatohepatitis and severe hypertriglyceridemia.

BiotechHealthtechMedical Devices

Founders & leadership

RPRohan Palekar
Rohan PalekarFounder · CEO2018–2026Rohan Palekar is founder and former CEO of 89bio, a biopharmaceutical company developing therapies for liver and cardiometabolic diseases. He previously served as President and CEO of Avanir Pharmaceuticals (CNS-focused specialty pharma) and held commercial and operational roles at Medivation and Johnson & Johnson's immunology division.

Investors · 3

Longitude Capitallisted by Longitude CapitalMenlo Park · $10M – $30M

How we know: Longitude Capital's portfolio page · the VCSheet dataset · Not right? Tell us

RA Capitallisted by RA CapitalBoston

How we know: RA Capital's portfolio page · Not right? Tell us

Frequently asked questions

What does 89bio (NASDAQ: ETNB) do?
A clinical-stage biopharmaceutical company developing investigational therapies for patients with liver and cardiometabolic diseases, with a lead candidate (pegozafermin) being evaluated for metabolic dysfunction-associated steatohepatitis and severe hypertriglyceridemia.
Who founded 89bio (NASDAQ: ETNB)?
89bio (NASDAQ: ETNB) was founded by Rohan Palekar.
Who are 89bio (NASDAQ: ETNB)'s investors?
89bio (NASDAQ: ETNB)'s investors include K2 HealthVentures, Longitude Capital, RA Capital.
Who acquired 89bio (NASDAQ: ETNB)?
89bio (NASDAQ: ETNB) was acquired by Roche.
Where is 89bio (NASDAQ: ETNB) headquartered?
89bio (NASDAQ: ETNB) is headquartered in San Francisco, US.